Hosking Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.2M | Buy |
69,009
+15,041
| +28% | +$4.33M | 0.69% | 50 |
|
|
2025
Q4 | $16.4M | Sell |
53,968
-159
| -0.3% | -$49.6K | 0.56% | 50 |
|
|
2025
Q3 | $15.2M | Buy |
54,127
+29
| +0.1% | +$7.89K | 0.55% | 54 |
|
|
2025
Q2 | $13.1M | Sell |
54,098
-393
| -0.7% | -$92.9K | 0.52% | 58 |
|
|
2025
Q1 | $13.3M | Sell |
54,491
-501
| -0.9% | -$151K | 0.56% | 57 |
|
|
2024
Q4 | $18.1M | Sell |
54,992
-7,118
| -11% | -$2.42M | 0.71% | 45 |
|
|
2024
Q3 | $20.8M | Sell |
62,110
-2,956
| -5% | -$939K | 0.8% | 43 |
|
|
2024
Q2 | $17.8M | Sell |
65,066
-3,941
| -6% | -$1.15M | 0.66% | 48 |
|
|
2024
Q1 | $23.9M | Sell |
69,007
-214
| -0.3% | -$70.4K | 0.88% | 37 |
|
|
2023
Q4 | $22.4M | Sell |
69,221
-5,005
| -7% | -$1.57M | 0.94% | 33 |
|
|
2023
Q3 | $26.6M | Buy |
74,226
+3,535
| +5% | +$1.36M | 1.18% | 31 |
|
|
2023
Q2 | $26.8M | Buy |
70,691
+18,401
| +35% | +$7.49M | 1.13% | 32 |
|
|
2023
Q1 | $25M | Sell |
52,290
-10,762
| -17% | -$5.04M | 1.16% | 29 |
|
|
2022
Q4 | $26.5M | Buy |
63,052
+14,294
| +29% | +$5.77M | 1.07% | 33 |
|
|
2022
Q3 | $20.3M | Sell |
48,758
-3,306
| -6% | -$1.65M | 0.89% | 33 |
|
|
2022
Q2 | $25.8M | Sell |
52,064
-10,282
| -16% | -$5.35M | 1.02% | 28 |
|
|
2022
Q1 | $35.1M | Sell |
62,346
-1,399
| -2% | -$843K | 0.91% | 29 |
|
|
2021
Q4 | $48.2M | Sell |
63,745
-1,225
| -2% | -$917K | 1.16% | 25 |
|
|
2021
Q3 | $48.5M | Sell |
64,970
-7,903
| -11% | -$5.92M | 1.2% | 22 |
|
|
2021
Q2 | $47M | Sell |
72,873
-1,005
| -1% | -$612K | 1.04% | 27 |
|
|
2021
Q1 | $42.2M | Sell |
73,878
-2,827
| -4% | -$1.67M | 0.99% | 27 |
|
|
2020
Q4 | $44.7M | Sell |
76,705
-2,685
| -3% | -$1.53M | 1.15% | 23 |
|
|
2020
Q3 | $40.9M | Sell |
79,390
-2,796
| -3% | -$1.42M | 1.26% | 20 |
|
|
2020
Q2 | $37.1M | Sell |
82,186
-6,038
| -7% | -$2.66M | 1.14% | 22 |
|
|
2020
Q1 | $30.9M | Sell |
88,224
-2,977
| -3% | -$1.09M | 1.08% | 24 |
|
|
2019
Q4 | $33.7M | Sell |
91,201
-3,673
| -4% | -$1.29M | 0.82% | 31 |
|
|
2019
Q3 | $31.6M | Sell |
94,874
-4,748
| -5% | -$1.55M | 0.82% | 34 |
|
|
2019
Q2 | $31.1M | Sell |
99,622
-727
| -0.7% | -$218K | 0.76% | 38 |
|
|
2019
Q1 | $30.7M | Sell |
100,349
-505
| -0.5% | -$136K | 0.78% | 37 |
|
|
2018
Q4 | $23.4M | Buy |
100,854
+4,041
| +4% | +$1.08M | 0.67% | 44 |
|
|
2018
Q3 | $30.3M | Sell |
96,813
-2,517
| -3% | -$781K | 0.67% | 40 |
|
|
2018
Q2 | $28.7M | Buy |
99,330
+582
| +0.6% | +$161K | 0.63% | 43 |
|
|
2018
Q1 | $24.7M | Buy |
98,748
+4,304
| +5% | +$1.1M | 0.55% | 56 |
|
|
2017
Q4 | $22.5M | Buy |
94,444
+6,586
| +7% | +$1.6M | 0.52% | 57 |
|
|
2017
Q3 | $19.5M | Buy |
87,858
+371
| +0.4% | +$83.5K | 0.51% | 54 |
|
|
2017
Q2 | $19.8M | Buy |
87,487
+1,407
| +2% | +$307K | 0.52% | 51 |
|
|
2017
Q1 | $17.2M | Buy |
86,080
+7,789
| +10% | +$1.5M | 0.48% | 59 |
|
|
2016
Q4 | $14.3M | Sell |
78,291
-2,003
| -2% | -$341K | 0.46% | 57 |
|
|
2016
Q3 | $13.2M | Buy |
80,294
+9,528
| +13% | +$1.45M | 0.44% | 61 |
|
|
2016
Q2 | $10.1M | Buy |
70,766
+9,448
| +15% | +$1.35M | 0.42% | 70 |
|
|
2016
Q1 | $8.38M | Buy |
61,318
+4,563
| +8% | +$599K | 0.38% | 75 |
|
|
2015
Q4 | $7.87M | Buy |
56,755
+11,467
| +25% | +$1.59M | 0.36% | 75 |
|
|
2015
Q3 | $6.08M | Buy |
+45,288
| New | +$6.52M | 0.3% | 83 |
|
Other funds holding BIO
VCM
VPM
AI
Hosking Partners's BIO Position: Q1 2026 in Review
Hosking Partners increased its Bio-Rad Laboratories Class A (BIO) stake by 28% in Q1 2026, buying an estimated $4.33M and bringing the position to 69,009 shares worth $19.2M. The position accounts for 0.69% of the portfolio, ranked #50.
Hosking Partners first reported a position in BIO in Q3 2015 and has held it in 43 quarters since. The position peaked at $48.5M in Q3 2021. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.
- Hosking Partners held 69,009 shares of Bio-Rad Laboratories Class A worth $19.2M as of Q1 2026.
- Hosking Partners bought 15,041 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $4.33M.
- Bio-Rad Laboratories Class A made up 0.69% of Hosking Partners's portfolio in Q1 2026, its #50 holding.
- Hosking Partners first reported a position in Bio-Rad Laboratories Class A in Q3 2015 and has held it in 43 quarters since.
- Hosking Partners's Bio-Rad Laboratories Class A position peaked at $48.5M in Q3 2021.
- 391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.
Based on Hosking Partners's 13F filing for Q1 2026, filed 21 Apr 2026.